Update shared on 22 Nov 2025
Fair value Decreased 2.80%Teleflex's analyst price target has been revised downward by $3.57 to $124.14. Analysts cite modest reductions in expected profit margins and growth as driving factors for the update.
What's in the News
- Teleflex reported a non-cash goodwill impairment charge of $403.9 million for the third quarter ended September 30, 2025 (Key Developments).
- The company narrowed its full year 2025 GAAP revenue growth outlook to a range of 9.10% to 9.60% and decreased its earnings per share guidance to $(4.42) to $(4.22) because of reserve adjustments and lower-than-expected U.S. order rates for intra-aortic balloon pumps (Key Developments).
- Teleflex announced enrollment of the first patient in the DUBSTENT DIABETES trial, testing a dual-device strategy for PCI in diabetic patients to address persistent stent failure despite technological advances (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has decreased from $127.71 to $124.14, reflecting a modest downward revision.
- Discount Rate has risen slightly from 9.02% to 9.11%.
- Revenue Growth Forecast has edged down marginally from 8.07% to 8.04%.
- Net Profit Margin projection has declined from 16.71% to 15.90%.
- Future P/E ratio estimate has increased from 9.35x to 9.58x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.